T-Cell Activation

How T-cell activation works

A naive T cell is a quiet thing. It circulates through blood, lymph, and lymph nodes, scanning antigen-presenting cells for seconds at a time, then moving on. The number of naive cells specific for any single antigen is small — perhaps one in a million for a given epitope. Most cells will never encounter their match. But when one does, and only when three independent conditions are met simultaneously, that cell transforms from rare to dominant in a week.

Signal 1 is the lock and key. The T-cell receptor (TCR), randomly assembled in the thymus, binds a specific peptide-MHC complex on the APC. CD4 or CD8 co-receptors latch onto the same MHC molecule (class II for CD4, class I for CD8) and reinforce the contact. This is the specificity signal — it picks out which TCR clone is going to respond.

Signal 2 is the permission slip. The T cell carries CD28; only activated dendritic cells, macrophages, and B cells express the B7 family ligands CD80 and CD86 at high enough density. The APC has to be mature — it has to have recently received a danger signal through pattern-recognition receptors like TLRs that told it the antigen it's now displaying came from somewhere inflammatory. Without B7 engagement of CD28, signal 1 alone drives the T cell into anergy — a permanent functional silencing.

Signal 3 is the amplification and polarization signal. Activated T cells secrete IL-2 and upregulate the high-affinity IL-2 receptor (CD25), creating an autocrine loop that drives proliferation. The APC and surrounding cells secrete polarizing cytokines that determine T-helper subset: IL-12 from dendritic cells pushes Th1 (anti-viral, anti-intracellular bacterial); IL-4 pushes Th2 (anti-helminth, allergic); TGF-β + IL-6 pushes Th17 (anti-fungal, mucosal); TGF-β alone induces regulatory T cells; IL-6 with IL-21 favors follicular helper T cells that license B-cell responses in germinal centers.

Inside the T cell, the cascade is rapid. TCR engagement triggers Lck, ZAP-70, and LAT, activating three parallel pathways: PLC-γ produces DAG and IP3 (releasing calcium and activating PKC-θ); the calcium-calcineurin axis dephosphorylates NFAT, allowing nuclear translocation; PI3K-Akt drives metabolism and survival. NFAT, NF-κB, and AP-1 all converge on the IL-2 promoter, but each requires distinct upstream inputs that map onto the three-signal model — explaining why no single signal suffices.

Worked clinical example: priming a CD4 response after Tdap booster

An adult gets a Tdap vaccine. Within an hour, dendritic cells at the injection site engulf the alum-adjuvanted toxoid antigens, take up pattern-recognition signals from the adjuvant (alum activates NLRP3 inflammasomes; some adjuvants also engage TLR4), and start migrating to the draining axillary lymph node. The migration takes 12-24 hours; arriving dendritic cells display thousands of class II-bound tetanus toxoid peptides and upregulate CD80, CD86, and CD40 to high surface density.

In the lymph node T-cell zone, naive CD4 T cells flow past at roughly one contact every few seconds. A T cell whose TCR matches an HLA-DR-bound peptide pauses, forms an immunological synapse, and starts polarizing. Signal 2 is satisfied because dendritic cells are now fully mature. Signal 3 cytokines depend on the adjuvant — alum tends to push Th2, which favors antibody class switching to IgG1 (in mice, IgG1 and IgE; in humans, IgG1 and IgG4). The activated T cell upregulates CD25, begins consuming IL-2, and enters cell cycle within 24-48 hours.

By day 5, the founding clone has divided 8-10 times and reached roughly 10³ cells. By day 7-10, peak frequency is around 10⁵ matched cells in the entire body — about a tenth of a percent of total CD4 T cells, up from one in a million. Some of these become effector T helpers that license B cells in the same node's germinal center, driving the antibody response. About 5-10% become memory T cells that persist for years and respond faster to a second exposure. The protective antibody titer that shows up on the patient's lab work in two weeks is downstream of that single dendritic-cell-to-T-cell encounter in the lymph node.

The three signals compared

	Signal 1	Signal 2	Signal 3
Molecules	TCR + CD4/8 ↔ peptide-MHC	CD28 ↔ CD80/CD86 (B7)	IL-2, IL-12, IL-4, TGF-β, IL-6...
Provides	Antigen specificity	Permission (APC must be mature)	Proliferation + subset polarization
Source of restriction	Thymic V(D)J + selection	APC activation state	Pathogen/adjuvant context
If absent	No engagement, no signal	Anergy (silenced)	No proliferation, no effector function
Negative regulator	PD-1 (synapse), CTLA-4 (delayed)	CTLA-4 outcompetes CD28	Treg IL-2 consumption
Clinical target	TCR therapies (CAR-T, BiTE)	Abatacept (CTLA-4-Ig) blocks	Cytokine antibodies (anti-IL-6, etc.)
Timing	Initial contact	Reinforces over 30 min	Hours to days, autocrine

The two-signal model was proposed by Bretscher and Cohn in 1970 to explain self-tolerance. Signal 3 was added later when Mescher and others showed that even with TCR engagement and CD28 costimulation, CD8 T cells needed cytokine help (IL-12 or IL-2) to develop full effector function. The model is now a foundational architecture for designing vaccines, transplant regimens, and cancer immunotherapies.

Variants and pathway details

• CD28 vs ICOS. CD28 is the canonical signal-2 receptor for naive T cells. ICOS is a CD28-family member upregulated on activated and memory T cells; it binds ICOS-L and supports germinal center T follicular helper function. Patients with ICOS mutations have antibody deficiency despite normal naive T-cell function.
• CD40-CD40L. This is the reciprocal — the T cell tells the APC to mature. CD40L on activated CD4 T cells engages CD40 on dendritic cells, "licensing" them to fully prime CD8 T cells. CD40L deficiency (X-linked hyper-IgM syndrome) impairs both T-cell help to B cells and CD8 cross-priming.
• Negative costimulators. PD-1 (on T cell) ↔ PD-L1 (on APC, tumor, IFN-γ-induced); LAG-3 ↔ MHC II; TIM-3 ↔ galectin-9; TIGIT ↔ CD155. All are induced on chronically stimulated T cells and contribute to "exhaustion."
• Superantigens. Bacterial toxins like staphylococcal enterotoxin B bridge MHC II to TCR Vβ chains outside the normal antigen-binding groove, activating 5-20% of T cells regardless of antigen specificity. The resulting massive cytokine release causes toxic shock syndrome.
• Anergy. Sustained calcium signaling without Ras-ERK activation induces transcription factors NFAT and Egr2/3 without AP-1, driving expression of anergy genes (Cbl-b, Itch, GRAIL, DGK-α) that desensitize TCR signaling. Anergic cells persist for years and require IL-2 + costimulation to break, which is partly how Treg-derived IL-2 deprivation maintains the state.
• CAR-T cells. Chimeric antigen receptors fuse an antibody-derived scFv (replacing the TCR/MHC requirement) to intracellular CD3-ζ plus CD28 and/or 4-1BB signaling domains — engineering signals 1 and 2 onto a single receptor that doesn't need MHC. This is why CAR-T works against tumors that have downregulated MHC.

Disease relevance

• Cancer immunotherapy. Checkpoint inhibitors (anti-CTLA-4 ipilimumab, anti-PD-1 nivolumab/pembrolizumab, anti-PD-L1 atezolizumab) release brakes on T-cell activation. Durable responses in 15-50% of treated patients depending on tumor type. Combination ipi+nivo in advanced melanoma achieves ~50% 5-year survival vs ~5% with chemotherapy alone.
• Transplant rejection. Abatacept (CTLA-4-Ig) and belatacept are fusion proteins that bind B7 on APCs, blocking CD28 and inducing anergy in alloreactive T cells. Used in kidney transplant maintenance to spare calcineurin inhibitor toxicity.
• Autoimmunity. Defective regulatory mechanisms allow self-reactive T cells to activate. CTLA-4 polymorphisms predispose to type 1 diabetes, Graves' disease, and others. Abatacept is approved for rheumatoid arthritis and juvenile idiopathic arthritis on the same B7-blocking mechanism.
• Immunodeficiency. Severe combined immunodeficiency (SCID) variants can affect every component of the activation pathway — IL-7R deficiency blocks T-cell development; ZAP-70 deficiency blocks signal 1 transduction; CD40L deficiency blocks T-cell help. All cause failure to thrive and lethal infections in infancy.
• Cytokine release syndrome. Hyperacute T-cell activation (CAR-T treatment, anti-CD3 in transplant, superantigen exposure) releases massive IFN-γ, IL-6, TNF — high fever, hypotension, capillary leak, multi-organ failure. Tocilizumab (anti-IL-6R) reverses it.
• HIV. Sustained TCR stimulation by viral antigens drives CD4 T-cell exhaustion (PD-1, LAG-3, TIM-3 upregulation) and depletion. Antiretroviral therapy restores T cells but exhaustion markers persist; checkpoint blockade is being investigated for HIV cure strategies.

Common pitfalls and misconceptions

• "All T-cell stimulation activates." Without all three signals, you get anergy, deletion, or regulatory T-cell induction. The default outcome of antigen exposure to a resting APC is tolerance, not immunity. This is why vaccines need adjuvants.
• "Stronger TCR signal is always better." Too strong drives activation-induced cell death; too weak fails to commit. T-cell development in the thymus selects for an intermediate affinity range. In peripheral activation, the analog signal strength tunes effector versus memory fate, and exhausts T cells under chronic stimulation.
• "T cells kill on contact with any cell displaying their antigen." Naive T cells can't kill anything until they've been primed by an APC — needs all three signals plus 3-5 days. After priming, effector CD8s kill efficiently, but they still need TCR engagement of cognate peptide-MHC on the target.
• "Cytokines act systemically." Most signal-3 cytokines act locally at the synapse and in the immediate microenvironment. Systemic IL-2 (high-dose for renal cell carcinoma) does work but causes severe toxicity precisely because of off-target effects.
• "Anergy is reversible by giving more antigen." No — more signal 1 deepens anergy. Reversal requires IL-2 plus strong costimulation, ideally with the original APC removed. This is why anergized self-reactive T cells stay safe.
• "Memory T cells skip the three-signal requirement." Memory T cells need less costimulation and respond faster, but they still require TCR engagement, and they're more sensitive to PD-1/CTLA-4 inhibition. The differences are quantitative, not categorical.

Therapeutic applications

• Vaccine adjuvants. Adjuvants (alum, MF59, AS01, AS03, lipid nanoparticles for mRNA) deliver signals through pattern-recognition receptors that mature dendritic cells, enabling signal 2 delivery. Different adjuvants polarize Th1 vs Th2 vs Tfh responses.
• Checkpoint inhibitors. Anti-CTLA-4 prevents B7 capture by CTLA-4, restoring CD28 access. Anti-PD-1/PD-L1 prevents inhibitory signaling at the synapse. LAG-3 inhibitors (relatlimab) approved in combination for melanoma in 2022.
• CAR-T therapy. Engineered T cells with built-in signals 1+2. Tisagenlecleucel and axicabtagene ciloleucel for leukemia/lymphoma. Cytokine release syndrome managed with tocilizumab and steroids.
• Costimulation blockade. Abatacept (CTLA-4-Ig) for rheumatoid arthritis, belatacept for kidney transplant. Both deliberately induce anergy in alloreactive/autoreactive T cells.
• Bispecific T-cell engagers (BiTEs). Blinatumomab links CD3 on T cells to CD19 on B-ALL cells, providing forced signal 1 in proximity to a tumor target — no MHC restriction needed. Approved for relapsed B-cell acute lymphoblastic leukemia.
• Treg therapy. Ex vivo expanded polyclonal or antigen-specific Tregs in transplant tolerance and type 1 diabetes trials. Aim is to suppress signal 3 IL-2 access and increase tolerogenic signals.